Eosinophilic Pneumonia

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Pneumonia

MalaCards integrated aliases for Eosinophilic Pneumonia:

Name: Eosinophilic Pneumonia 12 15 17 70
Pneumonia, Eosinophilic 12 73
Pulmonary Eosinophilia 44 70
Asthmatic Pulmonary Eosinophilia 70
Simple Pulmonary Eosinophilia 70
Pneumonia Eosinophilic 54


External Ids:

Disease Ontology 12 DOID:5870
MeSH 44 D011657
NCIt 50 C35150
SNOMED-CT 67 196145005
ICD10 32 J82.81
UMLS 70 C0034068 C0242459 C0340076 more

Summaries for Eosinophilic Pneumonia

Disease Ontology : 12 A pneumonia in which certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. It is caused by certain medications or environmental triggers, parasitic infections, and cancer. The most common symptoms include cough, fever, difficulty breathing, and sweating at night.

MalaCards based summary : Eosinophilic Pneumonia, also known as pneumonia, eosinophilic, is related to chronic eosinophilic pneumonia and loeffler syndrome, and has symptoms including hemoptysis and coughing. An important gene associated with Eosinophilic Pneumonia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Budesonide and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Eosinophilic pneumonia is a disease in which an eosinophil, a type of white blood cell, accumulates in... more...

Related Diseases for Eosinophilic Pneumonia

Diseases in the Eosinophilic Pneumonia family:

Chronic Eosinophilic Pneumonia

Diseases related to Eosinophilic Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 32.7 RNASE3 IL5 CD69 CCL5 CCL11
2 loeffler syndrome 31.5 IL5 IL33 IL13
3 bronchiolitis obliterans 30.5 SFTPD IL13 CXCL8
4 extrinsic allergic alveolitis 30.5 SFTPD CXCL8 CCL5
5 cytokine deficiency 30.4 IL5 IL13
6 sarcoidosis 1 30.4 SFTPD IL13 CD69 CCL5 CCL11
7 filarial elephantiasis 30.4 IL5 IL4 IL13
8 interstitial pneumonitis, desquamative, familial 30.3 SFTPD MUC1
9 cryptogenic organizing pneumonia 30.3 SFTPD MUC1 CXCL8
10 toxocariasis 30.2 RNASE3 IL5 IL4 IL13
11 ige responsiveness, atopic 30.1 RNASE3 IL5 IL4 IL13
12 respiratory failure 30.1 SFTPD RNASE3 IL5 IL13 CXCL8 CCL5
13 echinococcosis 30.1 RNASE3 IL5 CCL17
14 churg-strauss syndrome 30.0 RNASE3 IL5 IL3 CXCL8 CCL17 CCL11
15 paragonimiasis 30.0 RNASE3 IL5 IL13 CCL17
16 nonspecific interstitial pneumonia 30.0 SFTPD MUC1 IL13 CCR4
17 toxic oil syndrome 30.0 IL5 IL4
18 pulmonary fibrosis 30.0 SFTPD IL13 CXCL8 CCL22 CCL17
19 respiratory syncytial virus infectious disease 30.0 IL5 IL13 CCL5
20 allergic bronchopulmonary aspergillosis 30.0 SFTPD IL5 IL4 CCR4 CCL22 CCL17
21 cellulitis 29.9 RNASE3 IL5 CSF2
22 elephantiasis 29.9 RNASE3 IL5 IL4 IL13
23 cough variant asthma 29.9 RNASE3 IL5 IL4
24 granulocytopenia 29.8 IL3 CSF2
25 disseminated eosinophilic collagen disease 29.8 RNASE3 IL5 IL3 CCL17
26 pneumonia 29.8 SFTPD MUC1 IL5 IL4 IL13 CXCL8
27 wells syndrome 29.8 RNASE3 IL5 CXCL8
28 dendritic cell tumor 29.7 MUC1 CD69
29 ascaris lumbricoides infection 29.7 IL5 IL13 CXCL8
30 cutaneous t cell lymphoma 29.7 IL5 IL4 CCR4 CCL17
31 folliculitis 29.7 IL5 IL4 CCL5 CCL11
32 pemphigoid 29.6 IL5 IL4 IL13 CCL11
33 idiopathic interstitial pneumonia 29.6 SFTPD IL4 IL13 CXCL8
34 uveitis 29.5 IL4 CXCL8 CCL11
35 aspergillosis 29.5 SFTPD IL5 IL4 CXCL8 CSF2 CCL5
36 chronic urticaria 29.5 RNASE3 IL4 IL3 IL13
37 crohn's disease 29.4 IL4 IL13 CXCL8 CSF2
38 lymphoma, hodgkin, classic 29.3 IL3 IL13 CSF2 CCR4 CCL17
39 hypereosinophilic syndrome 29.3 RNASE3 IL5 IL4 IL3 IL13 CXCL8
40 peritonitis 29.3 IL4 CXCL8 CD69
41 schistosomiasis 29.3 RNASE3 IL5 IL4 IL33 IL13
42 celiac disease 1 29.2 IL5 IL4 IL13 CXCL8
43 erythema multiforme 29.2 IL5 IL4 CXCL8 CCL5 CCL17
44 chlamydia 29.2 IL5 IL4 CXCL8 CSF2
45 pulmonary eosinophilia 29.2 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
46 lung disease 29.2 SFTPD RNASE3 MUC1 IL5 IL4 IL13
47 leprosy 3 29.2 IL5 IL4 IL13 CXCL8 CSF2
48 bronchitis 29.1 RNASE3 IL5 IL4 IL13 CXCL8 CCL5
49 bronchiolitis 29.1 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
50 urticaria 28.8 RNASE3 IL5 IL4 IL3 IL13 CXCL8

Graphical network of the top 20 diseases related to Eosinophilic Pneumonia:

Diseases related to Eosinophilic Pneumonia

Symptoms & Phenotypes for Eosinophilic Pneumonia

UMLS symptoms related to Eosinophilic Pneumonia:

hemoptysis; coughing

MGI Mouse Phenotypes related to Eosinophilic Pneumonia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCL11 CCL17 CCL5 CCR4 CD69 CSF2
2 immune system MP:0005387 9.73 CCL11 CCL17 CCL22 CCL5 CCR4 CD69
3 respiratory system MP:0005388 9.23 CCL11 CCR4 CSF2 IL13 IL33 IL4

Drugs & Therapeutics for Eosinophilic Pneumonia

Drugs for Eosinophilic Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Omalizumab Approved, Investigational Phase 4 242138-07-4
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Benralizumab Approved, Investigational Phase 4 1044511-01-4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Gastrointestinal Agents Phase 4
15 Neuroprotective Agents Phase 4
16 Protective Agents Phase 4
17 Antiemetics Phase 4
18 Immunoglobulins Phase 4
19 Antibodies Phase 4
20 Antibodies, Monoclonal Phase 4
21 Formoterol Fumarate Phase 4
22 Budesonide, Formoterol Fumarate Drug Combination Phase 4
23 Anti-Bacterial Agents Phase 4
24 Anti-Infective Agents Phase 4
25 Antiviral Agents Phase 4
26 Anti-Allergic Agents Phase 4
27 Methylprednisolone Acetate Phase 4
28 glucocorticoids Phase 4
29 Hormone Antagonists Phase 4
30 Hormones Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Anti-Asthmatic Agents Phase 4
34 Respiratory System Agents Phase 4
35 Neurotransmitter Agents Phase 4
36 Adrenergic beta-Agonists Phase 4
37 Albuterol Phase 4
38 Adrenergic Agents Phase 4
39 Tocolytic Agents Phase 4
40 Bronchodilator Agents Phase 4
41 Adrenergic Agonists Phase 4
Reslizumab Approved, Investigational Phase 3 241473-69-8
43 Pharmaceutical Solutions Phase 3
44 Immunoglobulins, Intravenous Phase 3
45 Immunoglobulin G Phase 3
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
Pramipexole Approved, Investigational Phase 2 104632-26-0 59868 119570
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
Salmeterol xinafoate Phase 2 94749-08-3 56801

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Unknown status NCT03652376 Phase 4 Benralizumab
2 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy Recruiting NCT04710134 Phase 4
5 SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Recruiting NCT04159519 Phase 4 Symbicort®;Fasenra®;Ventolin®
6 Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial Recruiting NCT04319705 Phase 4 Azithromycin;Placebo oral tablet
7 How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma. Recruiting NCT04585997 Phase 4 Mepolizumab;Omalizumab
8 A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Recruiting NCT04228588 Phase 4 Mepolizumab 100 MG [Nucala]
9 Predictive Signature of Benralizumab Response Not yet recruiting NCT04565483 Phase 4 Benralizumab Prefilled Syringe
10 A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM) Not yet recruiting NCT04276233 Phase 4 Prednisone/ Prednisolone;Salbutamol
11 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
12 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
13 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
14 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
15 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
16 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
17 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
18 An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma Recruiting NCT04305405 Phase 3 Benralizumab
19 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
20 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
21 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
22 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
23 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
24 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
25 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
26 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Completed NCT04046939 Phase 2 dexpramipexole 75 mg/day;dexpramipexole 150 mg/day;dexpramipexole 300 mg/day;placebo oral tablet
27 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
28 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
29 Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma Recruiting NCT04674137 Phase 2 XC8 100 mg;Placebo
30 A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects Recruiting NCT04445038 Phase 1 610;Placebo
31 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
32 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Unknown status NCT03739320 Mepolizumab 100 MG Injection [Nucala]
33 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
34 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
35 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
36 Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Completed NCT04126499
37 Effects of Anti-IL5 Biological Treatments of Total Blood IgE Levels in Severe Asthmatic Patients: Real-life Retrospective Multicenter Observational Study Completed NCT04181190
38 Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin Recruiting NCT04414137
39 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
40 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
41 Identification of Autoantigens and Their Potential Post-translational Modification in EGPA and Severe Eosinophilic Asthma Recruiting NCT04671446
42 Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland Recruiting NCT03907137
43 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab
44 Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma Recruiting NCT04542902
45 Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils Recruiting NCT04538937
46 A Multicentre Single Arm Observational Prospective Study to Assess Demographic Characteristics Burden of Disease PRO's in Uncontrolled, Severe Eosinophilic Asthma Patients Aged 18y or Older and Qualifying for Treatment With Benralizumab in BE Recruiting NCT04221802
47 FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody Therapy Recruiting NCT04512521 Mepolizumab
48 imPROve-asthma - A Prospective, 24-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany Recruiting NCT04184284
49 Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction Recruiting NCT04612556 Mepolizumab 100 MG [Nucala]
50 Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting Recruiting NCT04187976

Search NIH Clinical Center for Eosinophilic Pneumonia

Cochrane evidence based reviews: pulmonary eosinophilia

Genetic Tests for Eosinophilic Pneumonia

Anatomical Context for Eosinophilic Pneumonia

MalaCards organs/tissues related to Eosinophilic Pneumonia:

T Cells, Lung, Bone Marrow, Breast, Skin, Myeloid, Thymus

Publications for Eosinophilic Pneumonia

Articles related to Eosinophilic Pneumonia:

(show top 50) (show all 1997)
# Title Authors PMID Year
[Total serum IgE levels in eosinophilic lung diseases]. 61 54
16883101 2006
Elevation of macrophage-derived chemokine in eosinophilic pneumonia: a role of alveolar macrophages. 61 54
15751278 2005
Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. 61 54
12757454 2003
Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. 61 54
11956056 2002
Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease. 61 54
11153599 2000
Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. 61 54
11031344 2000
Overexpression of CD44 on alveolar eosinophils with high concentrations of soluble CD44 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. 54 61
10688432 1999
[Evaluation of eosinophilic cationic protein levels in patients with eosinophilic pneumonia]. 54 61
9893428 1998
Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. 54 61
7921434 1994
[Expression of activation antigen, CD69, on human local eosinophils]. 54 61
8031251 1994
[Characterization of a receptor for interleukin-5 on pulmonary eosinophils with eosinophilic pneumonia]. 61 54
1306241 1992
[Ultrastructural observation of eosinophils in bronchoalveolar lavage fluid in eosinophilic pneumonia]. 61 54
1484434 1992
In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. 54 61
1500624 1992
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. 61
33098725 2021
Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. 61
33016513 2021
Clinical significance of invariant natural killer T cells and IL-5 in acute eosinophilic pneumonia. 61
33191121 2021
Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. 61
33450293 2021
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. 61
33434111 2021
Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic. 61
33792260 2021
Dupilumab: a Review of Present Indications and Uses Out Of Indication. 61
33661102 2021
Waterproofing spray-associated pneumonitis review: Comparison with acute eosinophilic pneumonia and hypersensitivity pneumonitis. 61
33725891 2021
The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. 61
32791083 2021
Immune checkpoint inhibitors-induced eosinophilic pneumonia: A case report. 61
33476070 2021
COVID-19 mimics on chest CT: a pictorial review and radiologic guide. 61
33296607 2021
Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia. 61
33441441 2021
CCR4-positive peripheral T-cell lymphoma presenting as eosinophilic pneumonia and developing from prolonged pustular psoriasis. 61
33641488 2021
[Sertraline-induced chronic eosinophilic pneumonia]. 61
33581985 2021
Daptomycin-Induced Acute Eosinophilic Pneumonia. 61
33786218 2021
Daptomycin associated eosinophilic pneumonia. 61
32098706 2021
Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab. 61
33636343 2021
Unusual presentation of chronic eosinophilic pneumonia with mild peripheral eosinophilia. 61
33542024 2021
Approach to Eosinophilia Presenting With Pulmonary Symptoms. 61
33002503 2021
Benralizumab as initial treatment for chronic eosinophilic pneumonia. 61
32807690 2021
Efficacy of Mepolizumab Extended Interval Dosing For Two Asthmatic Cases with Chronic Eosinophilic Pneumonia. 61
33502319 2021
Identification of Complex Pneumonia during the Outbreak of COVID-19: Bacterial Pneumonia Combined with Acute Eosinophilic Pneumonia in Patients with Maintenance Hemodialysis. 61
32721968 2021
Acute Eosinophilic Pneumonia Associated With SARS-CoV-2 Infection. 61
33446345 2021
Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. 61
33793625 2021
COVID-19 and its Mimics: What the Radiologist Needs to Know. 61
32852419 2021
[Lung imaging in severe asthma]. 61
33423858 2021
Experimental Modeling of Eosinophil-Associated Diseases. 61
33486743 2021
Adverse Reactions Induced by Minocycline: A Review of Literature. 61
33494681 2021
A case of hypereosinophilic syndrome with STAT5b N642H mutation. 61
33542831 2021
A Case of Interstitial Pneumonia with Features of Autoimmunity. 61
33261231 2020
Sertraline-Induced Acute Eosinophilic Pneumonia. 61
33457126 2020
Acute eosinophilic pneumonia accompanied with COVID-19: a case report. 61
33235798 2020
Dupilumab for chronic eosinophilic pneumonia. 61
33022880 2020
Leukotriene D4 paradoxically limits LTC4-driven platelet activation and lung immunopathology. 61
33285161 2020
Acute Eosinophilic Pneumonia and Heated Tobacco Products. 61
32713923 2020
Acute Eosinophilic Pneumonia Induced by Switching from Conventional Cigarette Smoking to Heated Tobacco Product Smoking. 61
32713912 2020
Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report. 61
32673881 2020

Variations for Eosinophilic Pneumonia

Expression for Eosinophilic Pneumonia

Search GEO for disease gene expression data for Eosinophilic Pneumonia.

Pathways for Eosinophilic Pneumonia

Pathways related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.98 RNASE3 MUC1 IL5 IL4 IL33 IL3
Show member pathways
13.76 MUC1 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
13.61 IL5 IL4 IL33 IL3 IL13 CXCL8
Show member pathways
13.51 IL5 IL4 IL3 IL13 CXCL8 CCL5
Show member pathways
13.34 IL5 IL4 IL3 IL13 CXCL8 CSF2
Show member pathways
13.25 MUC1 IL5 IL4 IL33 IL3 IL13
Show member pathways
13.13 IL5 IL4 IL3 IL13 CXCL8 CSF2
Show member pathways
12.87 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
Show member pathways
12.86 RNASE3 IL5 IL4 IL3 IL13 CXCL8
10 12.78 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
12.57 IL5 IL4 IL3 IL13 CSF2
Show member pathways
12.42 IL5 IL4 IL3 IL13 CSF2
Show member pathways
12.36 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
Show member pathways
12.31 IL5 IL4 IL13 CXCL8 CSF2 CCL17
Show member pathways
12.25 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
17 12.03 IL5 IL4 IL3 CSF2 CD69
18 12.01 MUC1 IL4 IL13 CXCL8 CCL22 CCL11
19 11.92 IL5 IL4 IL3 CSF2
20 11.85 IL5 IL4 IL13 CXCL8 CSF2
21 11.82 IL5 IL4 IL33 IL13
22 11.8 CXCL8 CSF2 CCL5
Show member pathways
11.8 IL5 IL4 IL3 CXCL8 CSF2
24 11.7 IL5 IL4 CCL17 CCL11
25 11.51 IL5 IL3 CSF2
26 11.42 IL4 IL13 CXCL8 CSF2 CCL5 CCL22
27 11.36 IL5 IL4 IL33 IL13
28 11.3 IL5 IL4 IL13 CXCL8 CSF2 CCL5
29 11.23 IL5 IL4 IL3 IL13 CSF2
30 11.22 IL5 IL4 IL13
31 10.85 IL5 IL4 IL13
32 10.83 IL5 IL4 IL33 IL13 CCL22 CCL17
33 10.76 IL5 IL4 IL3 IL13 CXCL8 CSF2

GO Terms for Eosinophilic Pneumonia

Cellular components related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 SFTPD RNASE3 MUC1 IL5 IL4 IL33
2 extracellular space GO:0005615 9.47 SFTPD RNASE3 MUC1 IL5 IL4 IL33

Biological processes related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.14 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
2 positive regulation of gene expression GO:0010628 9.99 IL4 IL33 IL13 CXCL8 CSF2
3 positive regulation of GTPase activity GO:0043547 9.96 CCL5 CCL22 CCL17 CCL11
4 MAPK cascade GO:0000165 9.93 IL5 IL3 CSF2 CCL5
5 inflammatory response GO:0006954 9.92 IL5 IL13 CXCL8 CCR4 CCL5 CCL22
6 cell-cell signaling GO:0007267 9.9 IL3 CCL5 CCL22 CCL17
7 cellular response to tumor necrosis factor GO:0071356 9.89 CXCL8 CCL5 CCL22 CCL17 CCL11
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 CCL5 CCL22 CCL17 CCL11
9 cellular response to interferon-gamma GO:0071346 9.84 CCL5 CCL22 CCL17 CCL11
10 response to virus GO:0009615 9.83 CCL5 CCL22 CCL11
11 cellular response to interleukin-1 GO:0071347 9.83 CXCL8 CCL5 CCL22 CCL17 CCL11
12 neutrophil chemotaxis GO:0030593 9.8 CXCL8 CCL5 CCL22 CCL17 CCL11
13 chemotaxis GO:0006935 9.8 RNASE3 CXCL8 CCR4 CCL5 CCL22 CCL17
14 cell chemotaxis GO:0060326 9.79 CCR4 CCL5 CCL22
15 monocyte chemotaxis GO:0002548 9.78 CCL5 CCL22 CCL17 CCL11
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 IL4 IL3 IL13 CSF2 CCL5
17 lymphocyte chemotaxis GO:0048247 9.76 CCL5 CCL22 CCL17 CCL11
18 positive regulation of B cell proliferation GO:0030890 9.74 IL5 IL4 IL13
19 positive regulation of immunoglobulin production GO:0002639 9.7 IL5 IL33 IL13
20 immune response GO:0006955 9.7 IL5 IL4 IL3 IL13 CXCL8 CSF2
21 macrophage activation GO:0042116 9.69 IL4 IL13 CSF2
22 positive regulation of macrophage activation GO:0043032 9.67 IL33 IL13
23 myeloid dendritic cell differentiation GO:0043011 9.67 IL4 CSF2
24 eosinophil chemotaxis GO:0048245 9.67 CCL5 CCL11
25 dendritic cell differentiation GO:0097028 9.65 IL4 CSF2
26 macrophage chemotaxis GO:0048246 9.65 SFTPD CCL5
27 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.64 CXCL8 CCL5
28 neutrophil activation GO:0042119 9.64 CXCL8 CCL5
29 positive regulation of podosome assembly GO:0071803 9.63 IL5 CSF2
30 chemokine-mediated signaling pathway GO:0070098 9.63 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL4 IL33
32 positive regulation of interleukin-13 production GO:0032736 9.62 IL4 IL33
33 positive regulation of mast cell degranulation GO:0043306 9.61 IL4 IL13
34 induction of bacterial agglutination GO:0043152 9.58 SFTPD RNASE3
35 negative regulation of complement-dependent cytotoxicity GO:1903660 9.56 IL4 IL13
36 positive regulation of cellular biosynthetic process GO:0031328 9.55 CXCL8 CCL5
37 cytokine-mediated signaling pathway GO:0019221 9.32 MUC1 IL5 IL4 IL3 IL13 CXCL8

Molecular functions related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 IL5 IL4 IL3 CSF2
2 CCR chemokine receptor binding GO:0048020 9.46 CCL5 CCL22 CCL17 CCL11
3 cytokine activity GO:0005125 9.36 IL5 IL4 IL33 IL3 IL13 CXCL8
4 chemokine activity GO:0008009 9.35 CXCL8 CCL5 CCL22 CCL17 CCL11
5 CCR4 chemokine receptor binding GO:0031729 9.26 CCL5 CCL17

Sources for Eosinophilic Pneumonia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....